SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing significant retail momentum as traders flock to the stock on rumors of a potential short squeeze, citing high short interest and speculative talk of a private buyout. Community members are actively sharing their positions and debating the brand's long-term value, creating a volatile environment driven by intense retail interest and discussions about leadership changes.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing significant downward pressure as investors rotate out of growth names and express concerns over shrinking margins and potential insider share dilution as the initial lock-up period expires. Despite announcing major long-term infrastructure deals with OpenAI and Amazon Web Services, the market is actively debating the company's valuation multiples and questioning whether its current revenue trajectory can justify its premium market cap.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is surging as investors react to analyst optimism regarding the company's AI-ready data center pipeline and its strategic positioning to benefit from growing energy demand. The community is actively debating the timing of potential lease agreements, with bulls pointing to the upcoming Russell 3000 inclusion and government support for nuclear-powered AI infrastructure as key catalysts for sustained long-term growth.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following a massive $700 million upsized public offering, which has sparked intense community debate over the impact of significant share dilution versus the company's strong institutional backing. While some investors interpret the upsized offering as a sign of confidence from large players in the company's upcoming clinical milestones, others are aggressively criticizing the move as a profit-taking exercise that leaves retail shareholders holding the bag.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely monitors a high-stakes legal dispute with Nippon Shinyaku, hoping for a swift resolution that grants Capricor independent control over the distribution of Deramiocel. Investors are simultaneously focused on the upcoming August PDUFA date and anticipation of positive clinical data, viewing the stock as a significant, high-asymmetric opportunity ahead of potential commercialization.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing significant downward pressure as market sentiment shifts and high-growth AI stocks face broad technical decompression. While the community remains divided between those viewing the recent price action as a temporary liquidity reset and others bracing for deeper retracement, investor focus remains firmly anchored on whether recent enterprise contract wins can effectively decouple the stock's fundamental growth narrative from current negative price momentum.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending as investors react to the company's fiscal third-quarter earnings beat and raised full-year guidance, which signaled resilience and effective cost-cutting despite geopolitical and inflationary pressures. The community is actively debating the stock's valuation as it nears record highs, with many focused on the upcoming Freight division spin-off as a key catalyst for long-term value creation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing downward pressure as investors closely scrutinize the massive capital expenditures required to maintain AI and cloud infrastructure dominance, despite strong growth projections for AWS. The community remains divided, with many viewing the current pullback as a discounted entry point for a long-term compounder, while others are concerned that the heavy AI spending cycle could strain margins and invite further regulatory scrutiny.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to the company's high-profile AI-driven partnership with Midjourney to develop medical imaging technology, sparking intense debate between long-term bulls betting on its semiconductor-based ultrasound platform and skeptics highlighting its persistent lack of profitability and insider selling. The community is actively weighing the potential for a massive short squeeze against concerns regarding the stock's elevated valuation and the long development runway for its newest product pipeline.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as traders react to leaked information about potential pre-order dates for Grand Theft Auto VI, driving significant anticipation ahead of the company's upcoming earnings report. The community is focused on the game's November release window and the potential for record-breaking engagement to act as a long-term catalyst for the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.read more...

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened...

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

Equity

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.


Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today

The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Telomir Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.25
Prev Close	$1.28
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	1.14
Avg. Volume	95,668.34
PE Ratio	-4.29

52-Week High	$3.10
52-Week Low	$1.05
Market Capitalization	$88.03M
EPS (Annual)	-$0.329
Price to Book	8.66
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

TELOTelomir Pharmaceuticals Inc

Latest TELO News